Introduction
Cytomegalovirus (CMV) is a double-stranded DNA virus and a member of the human herpesvirus family. 1 CMV infection is a common viral infection in humans, occurring in approximately 50% to 80% of adults, depending on the population studied. [2] [3] [4] Once the infection is acquired, CMV infection persists in a latent state, similar to other herpes virus infections. [4] [5] [6] [7] Viral replication of CMV, however, can be reactivated under conditions of immunosuppression, such as organ transplantation and immunosuppressive treatment. [4] [5] [6] The pathogenicity of CMV in a flare-up of ulcerative colitis (UC) remains unclear, but colonic CMV reactivation is considered to be an exacerbating factor in patients with UC patients refractory to immunosuppressive therapies because of the poor prognosis of UC patients with concomitant CMV infection. 4, [8] [9] [10] [11] [12] Furthermore, in addition to immunosuppressive treatment, the disease activity itself can predispose patients with UC to reactivation of latent CMV in the colonic tissues. 8, 9 Therefore, it is very important to establish optimal modalities of diagnosing colonic CMV reactivation.
Among the various modalities used to diagnose CMV infection, histological examination, including inclusion body and immunohistochemistry (IHC) for CMV, together with virological analysis using peripheral blood samples, such as serology, blood CMV viral load determined by antigenemia, and quantitative real-time polymerase chain reaction (PCR), have been mainstays of the diagnosis. In contrast, real-time PCR assay using colonic tissues samples (tissue PCR) is recommended by the European Crohn's and Colitis Organization guidelines as an alternative to IHC for CMV to investigate the presence of colonic CMV reactivation in immunomodulatory refractory cases of inflammatory bowel disease (IBD), because the CMV-DNA load can 5 Fukuchi, et al.
be high in colonic tissue even when IHC and other modalities using peripheral blood samples for CMV infection are all negative. 4 Yoshino et al. reported the usefulness of quantitative real-time PCR assays using colonic biopsy specimens for early detection of colonic CMV reactivation in patients with refractory UC, and demonstrated that colonic CMV reactivation occurred mainly in inflamed colonic mucosa. 13 Furthermore, Roblin et al. recently reported that CMV-DNA was detected in inflamed intestinal tissues whereas no trace of the CMV-DNA was detected in the endoscopically normal colonic tissue. 14 Of note, the patients enrolled in their study were all naïve to intravenous corticosteroids or cyclosporine treatment, which generally lead to colonic CMV reactivation with histological lesions. These data suggest that colonic CMV reactivation in inflamed tissue might easily occur in a subpopulation of active UC patients without immunosuppressive treatment, depending on their immune condition. Therefore, it is clinically important to check the CMV-DNA load in colonic tissue for monitoring CMV infection and selecting anti-inflammatory therapy without stimulating CMV reactivation.
Granulocyte and monocyte adsorptive apheresis (GMAA) is an extracorporeal therapy performed with the Adacolumn (JIMRO, Gunma, Japan), which selectively depletes granulocytes and monocytes from the peripheral blood. [15] [16] [17] Several previous studies reported achieving a high remission rate in patients with active UC following GMAA therapy, and Sakuraba's group and our data suggest that intensive GMAA (twice per week) induces higher clinical and endoscopic remission compared with weekly GMAA. 18, 19 In addition, our recent data and previous case series revealed that GMAA could be a suitable therapeutic option for patients with active UC prior to starting corticosteroid (CS) therapy because of a striking difference in the clinical response to 6 Fukuchi, et al.
GMAA between steroid-naïve and steroid-dependent patients. [19] [20] [21] Furthermore, it was recently reported that GMAA could be safe for UC patients with a history of CMV infection due to the avoidance of colonic CMV reactivation compared with UC patients treated with immunosuppressive drugs. 22 Theoretically, GMAA removes granulocytes and monocytes/macrophages, where CMV infection is latent and reactivates. GMAA does not affect colonic CMV reactivation. These findings together suggest that intensive GMAA might be optimal therapy for the induction of remission in UC patients with colonic CMV reactivation.
In the present study, we investigated (1) The rate of CMV infection in UC patients not receiving corticosteroids by using tissue PCR, and (2) compared the efficacy and safety of intensive GMAA between UC patients with CMV infection and UC patients without CMV infection.
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Materials and Methods

Patients
From January 2010 to July 2011, a total of 51 patients with moderate to severe active UC were enrolled in this study. 
Assessment of endoscopic severity
Endoscopic severity of UC was assessed using the Mayo Endoscopic Score
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(Mayo-ES) as follows: normal or inactive disease = score 0; erythema, decrease of vascular pattern and mild friability as mild disease = score 1; marked erythema, lack of vascular pattern, friability, erosions as moderate disease = score 2; spontaneous bleeding and ulceration as severe disease = score 3.
CMV antigenemia
The antigenemia assay was performed using a monoclonal antibody against a CMV structural protein of the 65 kDa lower-matrix phosphoprotein (C7HRP or C10C11).
Histopathological examination
Colonic biopsy specimens were obtained from inflamed colonic mucosa, fixed in formalin, embedded in paraffin, and stained with hematoxylin and eosin (H&E), and Jose, CA) as described previously. 7 Oligonucelotide primers specific for the immediate early gene were used for CMV-DNA amplification. The sequence of the upstream primer was 5'-GACTAGTGTGATGCTGGCCAAG-3', and that of the downstream primer was 5'-GCTACAATAGCCTCTTCCTCATCTG-3'. The 6-carboxyfluorescein-labeled probe was 5'-AGCCTGAGGTTATCAGTGTAATGAAGCGCC-3'. The PCR conditions were as follows: incubation at 95℃ for 10 min, 50 cycles of 95℃ for 15 s, followed by incubation at 62℃ for 1 min. Cases in which the CMV-DNA copy number was over 10 copies/µg DNA were defined as positive for CMV infection.
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Diagnosis of colonic CMV reactivation
Cases in which CMV was detected by at least one of the two methods above (histological examination with immunohistochemistry and/or quantitative real-time PCR) were diagnosed as positive for colonic CMV reactivation.
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Treatment
Intensive GMAA treatments were performed as previously described with no CS therapy and no antiviral therapy, irrespective of whether the patients were CMV positive or negative. 18, 19 The maximum number of GMAA sessions allowed was 10 ( Fig   1) . Blood access was obtained through the antecubital vein in one arm, and the return to the patient was through the antecubital vein in the contralateral arm, both through a 19-gauge needle. GMAA was performed at a flow rate of 30 mL/min for 60 min, with the aim to expose 1800 mL blood/session (one session). None of the UC patients positive for CMV received antiviral therapy, and adverse events were recorded at each visit during intensive GMAA.
Assessment
We investigated the detection rate of colonic CMV reactivation in patients with moderate to severe UC and without CS. Next, we examined the clinical factors related 
Statistical analysis
Data are presented as mean ± SE. Categorical and continuous data were compared using a two-tailed Fisher exact test and Student's t-test. A p value of less than 0.05 was considered statistically significant.
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Results
Clinical characteristics
The clinical characteristics of 51 UC patients without CS therapy are summarized in 
Detection rate of CMV infection in active UC patients without CS therapy
Of the 51 patients, 15 (29.4%) were diagnosed as positive for colonic CMV reactivation (Table 2) . CMV-DNA was detected in the inflamed colonic mucosa of all 15 patients, and histological examination was positive in three (6.7%) of these UC patients. Patients negative for CMV-DNA in the colonic mucosa were negative for both CMV antigenemia and histologic examination.
Differences in the clinical parameters between UC patients without CS therapy positive or negative for CMV
We compared differences in the age, sex, disease location, CAI, and Mayo-ES between CMV-positive and CMV-negative UC patients. Other than disease duration, these clinical parameters did not differ between groups (Table 3) . Importantly, the positive rate of CMV-DNA was significantly lower in UC patients treated with AZA/6MP than in those without (Table 3 ).
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Clinical efficacy of intensive GMAA treatment
Two weeks after starting intensive GMAA, 53.3% of UC patients that were CMV positive went into clinical remission compared with 52.7% of those who were CMV negative. At 6 weeks, 73.3% of the UC patients positive for CMV receiving intensive GMAA had a clinical remission in comparison with 69.4% of those negative for CMV (p = 0.781). There was no significant difference in the clinical remission rate following treatment with intensive GMAA between UC patients that were CMV positive and those that were CMV negative (Fig 1) . Mean time to clinical remission was 17. 
Mucosal healing induced by intensive GMAA treatment
We investigated the association between the efficacy of intensive GMAA on mucosal healing and CMV infection in patients with UC. Upon initiating intensive GMAA, the Mayo-ES was 2.2 ± 0.1 in patients with UC that were CMV-positive and 2.3 ± 0.1 in those that were CMV-negative (p = 0.786; Table 3 ). At 1 week after the completion of intensive GMAA, the Mayo-ES was 1.1 ± 0.3 in UC patients that were CMV-positive and 1.0 ± 0.2 in those that were CMV-negative (p = 0.829; Fig 2A) . There was no significant difference in the proportion of patients who achieved mucosal healing by intensive GMAA between patients with UC that were positive or negative for CMV 13 Fukuchi, et al.
(66.7% vs. 69.4%, p = 0.846; Fig 2B) .
Disappearance of CMV infection after intensive GMAA treatment in UC patients positive for CMV
To evaluate the effect of intensive GMAA on CMV infection in patients with UC, we compared the CMV-DNA load before and after intensive GMAA. At 1 week after the completion of intensive GMAA, 11 of 15 patients positive for CMV (73.3%) became negative for CMV (Table 4 ). In addition, all of these 11 patients achieved clinical remission only 1 week after the completion of intensive GMAA. Moreover, 10 of 11 patients (90.9%) simultaneously achieved mucosal healing (Table 4 ; Case1-11). On the other hand, four patients who were still positive for CMV at 1 week after the completion of intensive GMAA did not achieve clinical remission (Table 4 (Table 4 ; Cases 3-10, 13-15). In this study, we could not observe any difference of the effect of GMAA between the UC patients with CMV-DNA (+)/IHC (+) and those with CMV-DNA (+)/IHC (-).
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The factors associated to CMV persistence or clearance by intensive GMAA in patients with UC positive for CMV before treatment
We compared as age, sex, disease duration, disease location, previous treatment, copy numbers of mucosal-PCR, IHC positive rate, CAI and Mayo-ES between UC patients positive for CMV before treatment CMV persistence and clearance at 1 week after the completion of intensive GMAA. However, possible clinical factors associated with CMV persistence were not identified in this study (Table 5 ).
Discussion
The findings of the present study revealed that colonic CMV reactivation occurred in the inflamed colonic mucosa of patients with active UC that were not receiving CS therapy. Intensive GMAA was safe and effective for inducing rapid clinical remission in UC patients positive for CMV, resulting in the disappearance of CMV-DNA in their colonic mucosa. Further, our findings suggested that intestinal inflammation of UC could trigger the colonic CMV reactivation whether or not immunosuppressive therapies were used, and that GMAA is a promising therapy for UC with concomitant CMV infection and does not reactivate CMV.
CMV infection is a well-known complication in immunosuppressed patients, such as after bone marrow transplantation and HIV infection. 5, 6 CMV is associated with steroid refractoriness in IBD. 8, 9 The role of CMV in the induction of inflammation and its relationship with immunosuppressive therapies is not clear, however, because the virological criteria for diagnosing CMV infection are not standardized. reactivation. 31 Yoshino et al., however, demonstrated that the endoscopic findings did not differ between UC patients under immunosuppressive therapies that were positive or negative for CMV-DNA. 13 Roblin et al. reported the lack of a correlation between CMV-DNA tissue load and endoscopic findings. 14 In the present study, we observed no significant difference in the endoscopic score between UC patients without CS treatment that were positive or negative for CMV-DNA. Although these data suggest that the use of different criteria to define colonic CMV reactivation leads to different results, clearly distinguishing between UC patients that are CMV positive and those that are CMV negative by endoscopic findings alone is difficult.
There is no standardized therapeutic regimen for UC patients with concomitant CMV It is well established that the CMV-specific cluster of differentiation (CD) 4 + T-cells,
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CD 8 + T-cells, and γδ T-cells is important for controlling and restricting viral replication
in hosts with CMV persistent infection. 5, 6 The production of tumor necrosis factor (TNF)-α is strongly associated with colonic CMV reactivation. 5 The GMAA system used in this study is a natural biological therapy for selectively removing granulocytes/macrophages from the peripheral blood that reduces the production of inflammatory cytokines such as TNF-α, interleukin (IL)-6, and IL-8, without reducing lymphocytes. Moreover, the number of CD14 + monocytes producing TNF-α is reduced from the peripheral blood by GMAA. [33] [34] [35] These anti-inflammatory mechanisms of GMAA might comprise a promising treatment for UC patients with concomitant CMV infection. In fact, Yoshino et al. reported that GMAA did not induce colonic CMV reactivation in UC patients with a history of CMV infection. 22 In the present study, the clinical remission rate and mucosal healing following intensive GMAA did not differ significantly between UC patients positive for CMV and UC patients negative for CMV.
A similar tendency was observed for the mucosal healing ratio. Notably, CMV-DNA in the colonic mucosa became negative in all UC patients positive for CMV that achieved clinical remission after intensive GMAA. These data strongly suggest that GMAA could be an optimal therapeutic strategy for patients with active UC that are CMV-positive.
In conclusion, our mucosal PCR data demonstrated that 29.4% of patients with active UC prior to the administration of CS were positive for CMV. This finding indicates that local intestinal inflammation can trigger colonic CMV reactivation in a subpopulation of patients with active UC. Additional immunosuppressive therapies, including CS, might also induce colonic CMV reactivation in these patients, yielding refractory UC.
Moreover, our present data showed that intensive GMAA therapy was promising for The clinical remission rate following intensive GMAA. There was no significant difference in the clinical remission rate following intensive GMAA treatment between UC patients positive for cytomegalovirus (CMV) and UC patients negative for CMV.
Figure 2
Mayo Endoscopic Score and mucosal healing rate at 1 week after the completion of intensive GMAA treatment. The Mayo Endoscopic Score was not significantly different at 1 week after completing the intensive GMAA treatment between UC patients that were CMV-positive and those that were CMV-negative (A). The mucosal healing rate was not significantly different at 1 week after completing the intensive GMAA treatment between UC patients that were CMV-positive and those that were CMV-negative (B). 
